Original Research Article

doi: http://dx.doi.org/10.20546/ijcmas.2016.502.050

Study of the Impact of Hepatitis D Virus Infection on Chronic Hepatitis B Virus Patients in Egypt

Mohamed Abdel-Hamid Ahmed¹, Mostafa Saleh Abdel-Motaleb Sheemy², Nagwa Sedky³, Gamal Esmat⁴ and Azza Abdul-Azim Gomaa⁵*

¹Medical Microbiology and Immunology Department, Faculty of Medicine, Minia University, Egypt
²Medical Microbiology and Immunology Department, Faculty of Medicine, Beni-Suef University, Egypt
³Medical Microbiology and Immunology, Faculty of Medicine, Cairo University, Egypt
⁴Tropical Medicine, Faculty of Medicine, Cairo University, Egypt
⁵Medical Microbiology and Immunology Department, Faculty of Medicine, Beni-Suef University, Egypt

*Corresponding author

ABSTRACT

Hepatitis D virus (HDV) is a defective virus that requires the presence of hepatitis B virus (HBV) for infection. It has been estimated that approximately 5% of the global hepatitis B surface antigen (HBsAg) carriers are also co-infected with HDV, leading to a total of 10–15 million HDV carriers worldwide. In the current study, we investigated anti-HDV seroprevalence, epidemiological features and effect of HDV on HBV morbidity and presence of HBe antigen markers among 216 HBsAg seropositive patients recruited from four hospitals in Egypt between October 2009 and October 2011. Anti-HDV assay was performed by enzyme immunoassay (EIA). Then, the HDV seropositive patients were further investigated for HBe antigen and antibody, HBV DNA and HBV genotyping. Out of 216 HBsAg positive patients, 32 (14.8%) were anti-HDV positive. This study confirmed a declining trend in the prevalence of HDV infection in Egypt. A suppressive effect of HDV on HBV replication was suggested from the lower rate of detection of HBeAg (3.13%), which is indirectly proportional to viral replication, and the higher rate of detection of HBeAb (75%) in anti-HDV positive patients.

Keywords
HDV, HBV, HBsAg, Viral replication, HBeAg, HBeAb, genotyping.

Article Info
Accepted: 23 January 2016
Available Online: 10, February 2016
Introduction

HDV is a defective virus that needs HBV as a helper virus (Asmah et al., 2014). Rizzetto and colleagues (1977) discovered HDV in the mid-1970s while they were trying to find out why some patients with HBV infection had more serious disease than others.

On electron microscopy, HDV appears as an enveloped, spherical particle of around 36 nm in diameter. The outer coat of the virion containing host lipids and the HBs Ags surrounds an inner nucleocapsid consisting of viral ribonucleoproteins (RNPs) with the genomic RNA and about 200 molecules of hepatitis D antigen (HDAg) per genome. HDV has the smallest RNA genome (about 1700 nucleotides) of all known animal viruses. However, it is comparable, although larger, to viroid RNAs, pathogenic agents of higher plants (Manesis et al., 2007). Replication of the HDV RNA is proposed to occur by a double rolling-circle mechanism, similar to that proposed for the replication of plant viroids and small satellite RNAs of some plant viruses (Taylor, 2014).

HBV infection is a global health problem, and over 350 million people around the world are chronic carriers of the virus. It has been estimated that approximately 5% of the global HBsAg carriers are also co-infected with HDV, leading to a total of 10–15 million HDV carriers worldwide (Farci and Niro, 2012). HDV appears to be endemic in the Middle East. A decline in the prevalence of both acute and chronic hepatitis D (CHD) has been observed worldwide (Mumtaz et al., 2005).

As HDV is enveloped by HBs Ag, it has similar transmission routes to those of HBV, with percutaneous exposure being the most important one (Su et al., 2006). HDV must either coinfect or superinfect with HBV infection (Koytak et al., 2007).

The pathogenesis of HDV remains controversial. In the acute stage, HDAg or HDV RNA may be directly cytotoxic to hepatocytes. In the chronic stage, inflammatory cells surround infected hepatocytes, and various autoantibodies have been detected in the serum of patients with CHD, suggesting the possible involvement of immune reaction in HDV pathogenesis (Huang et al., 2009).

HDV is dominant over HBV in the majority of cases (Heidrich et al., 2013). Co-infection and superinfection with HDV suppresses HBV replication in patients and in model systems. About 70–90% of patients with HDV co-infection are HBeAg negative, and most have low serum HBV DNA (Sagnelli et al., 2000 and Zachou et al., 2010).

Currently, Diagnosis of HDV infection can be achieved indirectly based on the detection of antibodies against HDAg (anti-HD). But still the most reliable tool to diagnose HDV infection is based on highly sensitive molecular techniques, reverse transcription-PCR (RT-PCR) (Koytak et al., 2007).

Till present, Interferon is the only therapy for chronic hepatitis D. Nucleos(t)ides analogues are not effective against the helper hepatitis B virus (Rizzetto, 2013). Compared to chronic hepatitis B or C, CHD treatment requires a higher dosage and a longer duration of treatment, and post-treatment relapses are common. In order to prevent the progression of CHD and its related morbidity and mortality, more effective treatments are needed (Hsieh et al., 2006).

HDV infection is distributed worldwide, although not uniformly, and it is estimated
that 5% of HBsAg carriers are also infected with HDV, which signifies that there might be between 15 and 20 million HDV-infected individuals (Rizzetto and Ciancio, 2012). This is a very rough number because it lacks data from areas where HBV is highly prevalent and HDV is poorly studied. HDV is highly endemic in Mediterranean countries, the Middle East, northern parts of South America, and Central Africa (Radjef et al., 2004). HDV also has high prevalence in Turkey (Bahcecioglu et al., 2011), Central Asia (Tsatsralt-Od et al., 2005), and the Amazonian region of Western Brazil (Paraná et al., 2006).

Egyptian studies conducted in 1990s demonstrated HDV antibodies in 23.53% in patients with chronic HBV (Darwish et al., 1992 and el-Zimaity et al., 1993). A later study detected anti-HDV in 20% of HBsAg positive subjects (Saudy et al., 2003).

The aim of this work was to determine the prevalence of HDV infection among HBsAg positive individuals either chronic hepatitis B cases or carriers, the association between HDV infection and the presence of HBe antigen marker that indirectly indicates viral replication and the correlation between HDV infection and the morbidity of HBV infection.

Materials and Methods

Study Population

This study was conducted on 216 patients who were seropositive for HBsAg. These patients were recruited from: hepatology clinics in National Hepatology and Tropical Medicine Research Institute, Beni-Suef University Hospital, Beni-Suef Insurance Hospital, El-Kahera El-Fatimya Hospital and from the inventory of National Hepatology and Tropical Medicine Research Institute during the period from October 2009 to October 2011.

History and Clinical Examination

History (in particular the history of blood transfusion, surgery, tooth extraction, wound sutures or intravenous drug use), demographic data (including sex, age and residence) and clinical data were obtained from all patients who were then subjected to thorough clinical examination (with stress on signs of chronic liver disease e.g.: jaundice, palmar erythema, spider naevi, lower limb edema, hepatomegaly, splenomegaly and ascites).

Routine Laboratory Investigations

The laboratory investigations have been done including, complete blood picture, aspartate transaminase (AST), alanine transaminase (ALT), serum bilirubin and prothrombin time.

Hepatitis Markers Testing

Total HDV antibodies were tested for in all patients [by Enzyme immunoassay (EIA), Diasorin Kit, Italy]. The thirty two patients (32/216) with positive HDV antibody were further investigated for HBeAg [by microparticle enzyme immunoassay (MEIA) technology, ABBOTT, Germany] and HBeAb [by MEIA technology, ABBOTT, Germany].

HBV DNA Detection and Genotyping

HBV DNA detection qualitatively by PCR [DNA extraction was carried by QIAamp DNA Mini Kits (Qiagen, Santa Clarita, USA) and PCR was performed using primers (table 1) from the S region of the HBV genome then the PCR products were electrophoresed on a agarose gel,
stained with ethidium bromide and evaluated under UV light. The sizes of PCR products (540 bp) were estimated according to the migration pattern of DNA ladder (Pharmacia Biotech, Piscataway, NJ, USA) and HBV genotyping by Restriction fragment length polymorphism (RFLP), (Boehringer Mannheim, Germany) using the restriction enzymes (Tsp509I and HinfI) digestion (Lindh et al., 1997).

Results and Discussion

Patients’ ages ranged from 18 to 65 years old, with mean age for anti-HDV positive patients 34.44±12.544 years and for anti-HDV negative patients was 29.46±11.42 years. With regard to gender, 23(71.9%) out of the 32 anti-HDV positive patients were males and 9(28.1%) were females (Table 2).

In anti-HDV positive patients mean of both ALT and AST were significantly elevated (p-values =0.017 and =0.006 respectively) and mean platelet count and prothrombin concentration were significantly decreased as compared to anti-HDV negative patients (p-values <0.01 and 0.001 respectively)(Table 3).

HBV-DNA PCR was detected in 16/32 (50%) anti-HDV positive patients and in 81/151 (53.6%) anti-HDV negative patients, a result that was statistically insignificant (p-value =0.71) (figures 1&2). Genotype D was the only genotype detected in HBV-HDV coinfected patients 16/16 (100%) (Figure 3).

The results of HBe antigen and antibody showed that in the anti-HDV positive patients only one patient (3.6%) was HBe Ag positive while 22 (75.9%) were HBe Ab positive and these were statistically significant (p-values <0.01 and 0.01 respectively).

HDV prevalence

The present study confirmed the declining trend in the prevalence of HDV infection in Egypt to 14.8 % (32/216 of the study group) with higher prevalence among older male patients.

This prevalence is relatively low compared with earlier Egyptian studies that demonstrated HDV antibodies in 23.53% (Darwish et al., 1992 and el-Zimaity et al., 1993) and 20% (Saudy et al., 2003) of HBsAg positive subjects. Our results were in agreement with a study conducted by (Njoh and Zimmo, 1998) in Saudi Arabia in which 13.6% of HBV carriers (n = 81) were positive for anti-HDV.

This decrease in prevalence also paralleled the declining trend in the prevalence of HDV infection witnessed in some other countries. In Italy, the prevalence of anti-HDV among HBsAg carriers with liver diseases decreased from 25% in 1983 to 14% in 1992 (Navascues et al., 1995) then to only 8.3% in 1997 (Sagnelli et al., 1997). A similar decrease (from 15.1% in 1983 to 7.1% in 1992) has also been reported in Spain(Gaeta et al., 2000). In Taiwan, (Huo et al., 1997) reported a decrease in HDV infection from 23.7% in 1983 to 4.2% in 1995. A matter that can be attributed to many factors including implementation of a national anti-HBV vaccination program, introduction and wide use of disposable needles for blood sampling and other medical purposes in high-risk populations (Mast, 2006).

Effect of HDV On morbidity

In our study, HDV infection was associated with increased morbidity in the form of elevated mean of ALT and AST (p-values
=0.017 and =0.006 respectively) and reduced mean of platelet count and prothrombin concentration (p-values <0.01 and =0.001 respectively).

Similar results were shown in the published data by (Bahcecioglu et al., 2011) where ALT level was significantly elevated in chronic HDV patients (p-value= 0.028). Similarly, in another study there were 96/169 (56.8%) patients with raised ALT in HBV/HDV co-infection group as compared to 137/311 (44%) in HBV mono-infection, (p-value =0.008) (Mumtaz et al., 2011). However in another study ALT elevation was not significant in HDV-associated infection compared with HBV infection alone whether acute viral hepatitis (P=0.82) or chronic (P=0.77) (Saravanan et al., 2008).

**Effect of HDV on HBV Viremia and HBV Genotype Association**

In the present study, HBV-DNA, a direct marker of viral replication, was detected in a higher percentage of patients with HBV mono-infection 53.6% (81/151) as compared to HBV/HDV co-infection 50% (16/32). However this difference between both groups was statistically insignificant (p-value =0.71).

In the present study either HBV infected patients with or without HDV infection had lower percentage of HBV viremia than in other published data worldwide. This may be due to the high rate of spontaneous clearance of HBV in our region.

The obtained results are in contradiction with the data reported by Heidrich et al. (2012) suggesting suppressive effects of HDV on HBV irrespective to the phase of HBV infection. Moreover, in the study conducted by Mumtaz et al. (2011) they concluded that among HBV/HDV co-infection, 146/169 (86.4%) had suppressed HBV as compared to 231/311 (74.3%) patients with HBV mono-infection (p-value = 0.002). In another study a significant lower proportion of HBV replication was found in patients with HDV co-infection: 68.5% as compared with 89.3% in patients infected with HBV alone (Popescu et al., 2013). Both the small HDV p24 protein as well as the large HDV p27 protein may repress the HBV enhancers’ pIIE1 and pIIE2 and thereby inhibit HBV replication (Williams et al., 2009).

A number of possible factors could explain these results including disparity in the sample size between different studies, variation in the age groups studied, differences in the endemicity of HBV infection among geographical areas and virological features of patients (viral genotypes, mutants or co-infection with other viruses) (Albano et al., 1992 and Grob et al., 2000). Moreover, the sensitivity of the molecular biology techniques might clarify too(Palmer et al., 1996). Furthermore, molecular assays may be impaired by contamination problems causing false positive results in some studies or an inadequate detection limit causing false negative results in other studies (Hauhoefer et al 2004).

In our study, HDV-RNA was not tested for and so the detection of HDV antibody alone doesn't ensure active HDV replication or presence of the HBV repressor protein in patient’s serum. In addition, HBV DNA determination was made by a qualitative assay; hence evaluation of the impact of HDV on HBV DNA viremia in the studied patients wasn’t comprehensive.
### Table 1. The Sequences of Primers used for HBV DNA-PCR

| No | nt position | Type | Sequence |
|----|-------------|------|----------|
| P7 | 256–278     | S    | 5'-GTGGTGACTTCTCTCAATTTTC-3' |
| P8 | 796–776     | AS   | 5'-CGGTA(A/T)AAAGGGACTCA(A/C)GAT-3' |

### Table 2. Demographic Characteristics in Relation to Anti-HDV Results in the Studied Patients

| HDV assay | Demographic data | anti-HDV | Total (n=216) | P value |
|-----------|------------------|----------|---------------|---------|
|           |                  | Negative (n=184) | Positive (n=32) |         |
| Sex       | Female           | 25 (13.6%) | 9 (28.1%) | 34 (15.7%) | 0.037 (S) |
|           | Male             | 159 (86.4%) | 23 (71.9%) | 182 (84.3%) |
| Age       | Mean (SD)        | 29.46 (11.420) | 34.44 (12.544) | 0.026 |

### Table 3. Results of Routine Laboratory Investigations in Relation to Anti-HDV values in the Studied Patients

| anti-HDV | Number | Mean  | Std. Deviation | P value |
|----------|--------|-------|----------------|---------|
| ALT_40   | Positive | 32.00 | 53.35 | 44.26 | 0.017 (S) |
|          | Negative | 182.00 | 33.17 | 26.11 |
| AST_40   | Positive | 22.00 | 44.58 | 18.00 | 0.006 (S) |
|          | Negative | 102.00 | 31.88 | 19.50 |
| Tbil     | Positive | 22.00 | .91 | 0.40 | 0.526 |
|          | Negative | 96.00 | .84 | 0.45 |
| HGB      | Positive | 22.00 | 12.73 | 2.81 | 0.339 |
|          | Negative | 76.00 | 13.34 | 1.63 |
| RBC      | Positive | 22.00 | 4.62 | 0.97 | 0.409 |
|          | Negative | 70.00 | 4.79 | 0.82 |
| WBC      | Positive | 22.00 | 5.16 | 1.46 | 0.243 |
|          | Negative | 76.00 | 5.72 | 2.06 |
| PLTs     | Positive | 22.00 | 208.05 | 60.07 | <0.01 (S) |
|          | Negative | 76.00 | 255.18 | 50.48 |
| PC       | Positive | 22.00 | 77.32 | 8.15 | 0.001 (S) |
|          | Negative | 71.00 | 85.10 | 9.08 |

S=significant
In the study done by Schaper et al. (2010) they investigated virological patterns longitudinally over a period of 4–8 years in a retrospective-prospective approach and determined quantitative levels of HBV DNA, HDV RNA, and HBsAg. Importantly, and in contrast to conclusions drawn from previous cross-sectional approaches, the authors demonstrated a high frequency of fluctuating activity of either one or even both viruses. They revealed HBV-DNA quantitatively in sera of 56.7% (21/37) of untreated chronic HDV patients. Consequently, HDV cannot necessarily be considered as the “dominant” virus based on a single determination and the role of HBV replication for the pathogenesis of liver disease in hepatitis D should not be underestimated (Wedemeyer, 2010).

In the present study, genotyping was carried out for all HBV DNA positive cases among the anti-HDV positive group (16/32) i.e. HBV/HDV coinfection. Results showed that genotype D was the only genotype detected 16/16 (100%). These results came in accordance with previous Egyptian studies that reported the predominance of genotype D in Egypt (Saudy et al., 2003 and Zaky et al., 2010) both studies concluded that genotype D was the only genotype detected.

**Effect of HDV on HBe Ag and HBe Ab**

In the this study, there was a low rate of detection of HBeAg (3.6%) (P-values<0.01), and a high rate of detection of HBeAb (75.9%) in anti-HDV positive patients (p-values=0.01).

These results may be due to the fact that HBV type D has higher rates of precore and core mutations which might had lead to the absence of HBeAg in the majority of cases and that the higher rate of detection of HBeAb might be elicited before mutation and HBeAg disappeared either due to the mutations or the suppressive effect of HDV or both.

Our results are compatible with the published data by (Ichimura et al., 1988). They concluded that, HBeAg clearance was observed in a significantly higher proportion of HDV-superinfected carriers18/28 (64.3%) as compared with carriers without HDV infection 70/214 (32.7%) (P-value < 0.005), suggesting that HDV superinfection can be considered as an inducer factor of HBeAg clearance in HBV carriers. In another supportive study, anti-HBe was found more often in the serum of the hepatitis D infected patients (68.4%) (Jelićand Jelić, 1994). Similar results were reported by (Mumtaz et al., 2011).

The investigators found that a large proportion of the studied patients with HBV/HDV co-infection had HBeAg negative disease 75.7% (128/169) as compared to HBV mono-infected patients 60.5% (188/311) reproducing a statistically significant correlation (p-value =0.001). Also, in a cohort of 534 anti-HDV positive patients, HBeAg-positivity was detected in 71/534 patients (13.3%) (Heidrich et al., 2012).

In contrast to our results and those obtained by the previous investigators, Saudy and coworkers (2003) conducted a study with somewhat different grouping criteria of their patients, reporting that HBeAg positivity was significantly higher in the carriers of anti-HDV positive without HDV-RNA group 100% (6/6) than the other two groups [the anti-HDV positive with HDV-RNA group 22% (2/9) and the anti-HDV negative group 35% (21/60)] (p-value<0.05).
Possible explanations for this difference may be due the lower mutation rate in other HBV genotypes, difference in the cohort of the studies or due to the decrease in the specificity of HBeAb assay which had led to false positive results or decrease in the sensitivity of HBeAg assay which had led to false negative results but this is not our propable explanation since detection of HBeAb and HBeAg by MEIA technology (ABBOTT, Germany) is one of the good assays.

Another explanation may be that the trend of the disease in HBeAg-positive patients with hepatitis D has not been well established (Amini et al., 2011).

References

Albano, A., Pianetti, A., Biffi, M.R., et al. 1992. Prevalence of anti-HCV in subjects of various age groups. Eur J Epidemiol. 8: 309–311.

Amini, N., Alavian, S.M., Kabir, A., et al. 2011. Clinical Features and Seroepidemiology of Anti-HDV Antibody in patients With Chronic Hepatitis B Virus Infection in Iran: A Meta-Analysis. Hepat Mon. 11(12):960-967.

Asmah, R.H., Boamah, I., Afodzinu, M., et al. 2014. Prevalence of hepatitis D infection in patients with hepatitis B virus-related liver diseases in Accra, Ghana. West Afr J Med. 33(1):32-36.

Bahcecioglu, I., Aygun, C., Gozel, N., et al. 2011. hepatitis B patients in eastern Turkey: still a Prevalence of hepatitis delta virus (HDV) infection in chronic hepatitis B patients in eastern Turkey: still a serious problem to consider. J Viral Hepat. 18(7):518-524.

Darwish, M.A., Shaker, M., Raslan, O.S. and Abdel-Raouf, T. 1992. Delta virus infection in Egypt. J Egypt Public Health Assoc. 67 (1-2):147-161.

El-Zimaity, D.M., Hyams, K.C., Imam, I.Z., et al. 1993. Acute sporadic hepatitis E in an Egyptian pediatric population. Am J Trop Med Hyg. 48:372–376.

Farci, P. and Niro, G.A. 2012. Clinical features of hepatitis D. Semin Liver Dis. 32(3):228-236.

Gaeta, G.B., Stroffolini, T., Chiaramonte, M. et al. 2000. Chronic hepatitis D: a vanishing disease? An Italian multicenter study. Hepatology. 32:824—827.

Grob, P., Jilg, W., Bornhak, H., et al. 2000. Serological pattern ‘anti-HBc alone’: report on a workshop. J Med Virol. 62:450-455.

Haushofer, A.C., Hauer, R., Brunner, H., et al. 2004. No evidence of hepatitis B virus activity in patients with anti-HBc antibody positivity with or without anti-hepatitis C virus antibody positivity. J Clin Virol. 29(4):221-223.

Heidrich, B., Manns, M.P. and Wedemeyer, H. 2013. Treatment options for hepatitis delta virus infection. Curr Infect Dis Rep. 15(1):31-38.

Heidrich, B., Serrano, B.C., Idilman, R., et al. 2012. HBeAg-positive hepatitis delta: virological patterns and clinical long-term outcome. Liver Int. 32(9):1415-1425.

Hsieh, T.H., Liu, C.J., Chen, D.S. and Chen, P.J. 2006. Natural course and treatment of hepatitis D virus infection. J Formos Med Assoc. 105: 869–881.

Huang, C., Chang, S.C., Yang, H.C., et al. 2009. Clathrin-mediated post-Golgi membrane trafficking in the
morphogenesis of hepatitis delta virus. J Virol. 83: 12314–12324.
Huo, T.I., Wu, J.C., Lin, R.Y., et al. 1997. Decreasing hepatitis D virus infection in Taiwan: an analysis of contributory factors. J GastroenterolHepatol. 12: 747–751.
Ichimura, H., Tamura, I., Tsubakio, T., et al. 1988. Influence of hepatitis delta virus superinfection on the clearance of hepatitis B virus (HBV) markers in HBV carriers in Japan. J Med Virol. 26(1):49-55.
Jelić, D. and Jelić, O. 1994. The HBe antigen-antibody system and its relationship to epidemiological, histological and biochemical findings in patients with HBV+ HDV chronic liver diseases. Acta Med Croatica. 48(2):77-83.
Koytak, E., Yurdaydin, C. and Glenn, J. 2007. Hepatitis D. Curr Treat Options Gastroenterol. 10(6):456–463.
Lindh, M., Andersson, A.S., Gusdal, A. 1997. Genotypes, nt 1858 Variants, and Geographic Origin of Hepatitis B Virus Large-Scale Analysis Using a New Genotyping Method. The Journal of Infectious Diseases. 175: 1285–1293.
Manesis, E.K., Schina, M., Le Gal, F., et al. 2007. Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring. AntivirTher. 12: 381–388.
Mast, E.E. 2006. Advisory Committee on Immunization Practices (ACIP) A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. Centers for Disease Control. 54 (16): 1-31.
Mumtaz, K., Ahmed, U.S., Memon, S., et al. 2011. Virological and clinical characteristics of hepatitis delta virus in South Asia. Virol J. 20:8:312.
Mumtaz, K., Hamid, S., Adil, S., et al. 2005. Epidemiology and clinical pattern of hepatitis delta virus infection in Pakistan. J GastroenterolHepatol. 20: 1503–1507.
Navascues, C.A., Rodriguez, M., Sotorrio, N.G., et al. 1995. Epidemiology of hepatitis D virus infection: changes in the last 14 years. Am J Gastroenterol. 90: 1981–1984.
Njoh, J. and Zimmo, S. 1998. Prevalence of antibody to hepatitis D virus among HBsAg-positive drug-dependent patients in Jeddah, Saudi Arabia. East Afr Med J. 75:327–328.
Palmer, D.R., Perry, K.R., Mortimer, P.P., et al. 1996. Variation in the sensitivity of HBsAg screening kits. Transfus Med. 6(4): 311-317.
Paraná, R. Kay, A., Molinet, F., et al. 2006. HDV genotypes in the Western Brazilian Amazon region: a preliminary report. American Journal of Tropical Medicine and Hygiene. 75(3):475–479. [PubMed]
Popescu, G.A., Otelea, D., Gavriliu, L.C., et al. 2013. Epidemiology of hepatitis D in patients infected with hepatitis B virus in bucharest: A cross-sectional study. J Med Virol. 85(5):769-774.
Radjef, N., Gordien, E., Ivaniushina, V., et al. 2004. Molecular phylogenetic analyses indicate a wide and ancient radiation of african hepatitis delta virus, suggesting a Deltavirus genus of at least seven major clades. Journal of Virology.78 (5):2537–2544. [PMC free article] [PubMed]
Rizzetto, M. 2013. Current management of delta hepatitis. Liver Int. Suppl 1:195-197.
Rizzetto, M., Canese, M.G., Aricò, S., et al. 1977. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis
B virus in liver and in serum of HBsAg carriers. Gut. 18: 997–1003.

Rizzetto, M., Ciancio, A. 2012. Epidemiology of hepatitis D. Seminars in Liver Disease. 32(3):211–219.

Sagnelli, E., Coppola, N., Scolastico, C., et al. 2000. Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. Hepatology. 32: 1106–1110.

Sagnelli, E., Stroffolini, T., Ascione, A., et al. 1997. Decrease in HDV endemity in Italy. J Hepatol. 26: 20–24.

Saravanan, S., Velu, V., Kumarasamy, N., et al. 2008. Seroprevalence of hepatitis delta virus infection among subjects with underlying hepatic inhibitory diseases in Chennai, southern India. Trans R Soc Trop Med Hyg. 102(8):793–796.

Saudy, N., Sugauchi, F., Tanaka, Y., et al. 2003. Genotypes and phylogenetic characterization of hepatitis B and delta viruses in Egypt. J Med Virol. 70(4):529–536.

Schaper, M., Rodriguez-Frias, F., Jardi, R., et al. 2010. Quantitative longitudinal evaluation of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic complex replicative profile in chronic hepatitis B and D. J Hepatol. 52:658–664

Su, C.W., Huang, Y.H., Huo, T.I., et al. 2006. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology. 130: 1625–1635.

Taylor, J.M. 2014. Host RNA circles and the origin of hepatitis delta virus. World J Gastroenterol. 20(11):2971–2978.

Tsatsralt-Od, B., Takahashi, M., Nishizawa, T., et al. 2005. High prevalence of dual or triple infection of hepatitis B, C, and delta viruses among patients with chronic liver disease in Mongolia. Journal of Medical Virology. 77(4):491–499. [PubMed]

Wedemeyer, H. 2010. Re-emerging interest in hepatitis delta: new insights into the dynamic interplay between HBV and HDV. J Hepatol. 52(5):627–629.

Williams, V., Brichler, S., Radjef, N., et al. 2009. Hepatitis delta virus proteins repress hepatitis B virus enhancers and activate the alpha/beta interferon-inducible MxA gene. J Gen Virol. 90:2759–2767.

Zachou, K., Yurdaydin, C., Drebber, U., et al. 2010. Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. Liver Int. 30: 430–437.

Zaky, S., Farghaly, A.M., Rashed, H.A., et al. 2010. Clinicopathologic features and genotyping of patients with chronic HBV infection in the Upper Egypt. Cell Immunol. 265(2):97–104.

How to cite this article:

Mohamed Abdel-Hamid Ahmed, Mostafa Saleh Abdel-Motaleb Sheemy, Nagwa Sedky, Gamal Esmat and Azza Abdul-Azim Gomaa. 2016. Study of the Impact of Hepatitis D Virus Infection on Chronic Hepatitis B Virus Patients in Egypt. Int.J.Curr.Microbiol.App.Sci. 5(2): 449-458. doi: http://dx.doi.org/10.20546/ijcmas.2016.502.050